234 related articles for article (PubMed ID: 23534949)
1. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Fabre C; Mimura N; Bobb K; Kong SY; Gorgun G; Cirstea D; Hu Y; Minami J; Ohguchi H; Zhang J; Meshulam J; Carrasco RD; Tai YT; Richardson PG; Hideshima T; Anderson KC
Clin Cancer Res; 2012 Sep; 18(17):4669-81. PubMed ID: 22806876
[TBL] [Abstract][Full Text] [Related]
3. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
[TBL] [Abstract][Full Text] [Related]
4. NF-κB dysregulation in multiple myeloma.
Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
[TBL] [Abstract][Full Text] [Related]
5. [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
Wang H; Liu X; Xu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):531-7. PubMed ID: 18549623
[TBL] [Abstract][Full Text] [Related]
6. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
8. The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma.
Vrábel D; Pour L; Ševčíková S
Blood Rev; 2019 Mar; 34():56-66. PubMed ID: 30501907
[TBL] [Abstract][Full Text] [Related]
9. TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Cell Cycle; 2016; 15(4):559-72. PubMed ID: 26743692
[TBL] [Abstract][Full Text] [Related]
10. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
11. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
13. [Proteasome inhibitors in treatment of multiple myeloma].
Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
[TBL] [Abstract][Full Text] [Related]
14. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
15. Signaling Pathways and Emerging Therapies in Multiple Myeloma.
Ramakrishnan V; D'Souza A
Curr Hematol Malig Rep; 2016 Apr; 11(2):156-64. PubMed ID: 26922744
[TBL] [Abstract][Full Text] [Related]
16. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
Anwer F; Gee KM; Iftikhar A; Baig M; Russ AD; Saeed S; Zar MA; Razzaq F; Carew J; Nawrocki S; Al-Kateb H; Cavalcante Parr NN; McBride A; Valent J; Samaras C
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):397-405. PubMed ID: 31036508
[TBL] [Abstract][Full Text] [Related]
17. Transcription factor NF-κB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies.
Fuchs O
Curr Mol Pharmacol; 2010 Nov; 3(3):98-122. PubMed ID: 20594187
[TBL] [Abstract][Full Text] [Related]
18. New proteasome inhibitors in myeloma.
Lawasut P; Chauhan D; Laubach J; Hayes C; Fabre C; Maglio M; Mitsiades C; Hideshima T; Anderson KC; Richardson PG
Curr Hematol Malig Rep; 2012 Dec; 7(4):258-66. PubMed ID: 23065395
[TBL] [Abstract][Full Text] [Related]
19. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
Zhao Y; Zhang K; Li G; Zhang X; Shi D
PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
[TBL] [Abstract][Full Text] [Related]
20. Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects.
Chen H; Li M; Sanchez E; Wang CS; Lee T; Soof CM; Casas CE; Cao J; Xie C; Udd KA; DeCorso K; Tang GY; Spektor TM; Berenson JR
Mol Cancer Res; 2017 May; 15(5):598-609. PubMed ID: 28122920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
